{
    "distances": [
        [
            0.8908129334449768,
            0.910719633102417,
            0.952938973903656,
            0.9625312089920044,
            0.9780901670455933,
            0.985551118850708,
            0.9940872192382812,
            0.9971200227737427,
            0.9997413158416748,
            1.0017757415771484
        ]
    ],
    "results": [
        "Celltrion Submits BLA for Tocilizumab Biosimilar On January 28, 2024, Celltrion USA announced that it has completed submission of its application to the FDA for CT-P47, its proposed tocilizumab biosimilar.\u00a0 CT-P47 references Genentech\u2019s ACTEMRA, an interleukin 6 receptor antagonist indicated for adult rheumatoid arthritis, juvenile idiopathic polyarthritis, and systemic juvenile idiopathic arthritis.\u00a0 \n\nCelltrion\u2019s Chief Commercial Officer, Thomas Nusbickel, said \u201c[t]he submission of CT-P47 for review is an important step toward providing patients with rheumatoid arthritis a more accessible avenue to treatment for conditions that present such a significant disease burden.\u201d\u00a0 \n\nCelltrion\u2019s BLA for CT-P47 is the third reported BLA for a tocilizumab biosimilar, following applications by Fresenius Kabi and Biogen, the latter of which was approved in September 2023.\n\nFDA Accepts Accord BioPharma\u2019s BLA for Ustekinumab Biosimilar On January 4, 2024, Accord BioPharma, Inc.\n\n(\u201cAccord\u201d) announced that the FDA has accepted for review a BLA for DMB-3115, a biosimilar candidate to Janssen\u2019s STELARA (ustekinumab).\n\nSTELARA is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn\u2019s disease, and ulcerative colitis.\u00a0 \n\nDMB-3115 was developed jointly with Dong-A Socio Holdings and Meiji Seika Pharma., with exclusive commercialization rights granted to Intas Pharmaceuticals.\n\nAccord, a global subsidiary of Intas Pharmaceuticals, will be responsible for U.S. commercialization. \u00a0\n\nIn October 2023, Accord settled with Janssen Biotech under confidential terms that would allow Accord to launch its proposed ustekinumab biosimilar no later than May 15, 2025, pending FDA approval.\n\nEMA Accepts Formycon\u2019s MAA for Aflibercept Biosimilar On December 27, 2023, Formycon and its license partner Klinge Biopharma GmbH announced that the European Medicines Agency (\u201cEMA\u201d) has accepted for review its Marketing Authorization Application (\u201cMAA\u201d) for FYB203, a biosimilar candidate to Regeneron\u2019s EYLEA.\u00a0 \n\nAflibercept is used in the treatment of neovascular age-related macular degeneration and other retinal diseases.\u00a0 \n\n\u201cWith the recent EMA acceptance for our ophthalmological biosimilar candidate FYB203, we are an important step closer to providing another effective treatment option \u2013 in addition to our already launched biosimilar FYB201 (ranibizumab) \u2013 to the many patients affected by severe retinal diseases in Europe,\u201d said Formycon CEO Dr. Stefan Glombitza. \u00a0\n\nAs we previously reported , Formycon\u2019s aBLA for FYB203 was accepted for review by the FDA in August 2023.\n\nThe post Biosimilar Regulatory Updates appeared first on Big Molecule Watch .",
        "On April 5, 2023, Accord BioPharma announced that the FDA has accepted the Biologics License Application (BLA) for HLX02 referencing HERCEPTIN (trastuzumab) for adjuvant treatment of HER2-overexpressing breast cancer and treatments of HER-2 overexpressing metastatic breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma.\n\nThe BLA submission included results from different studies comparing the structural and functional similarities between HLX02 and reference trastuzumab.\n\nHLX02 was originally developed by Shanghai Henlius Biotech and was approved by the European Commission and China\u2019s National Medical Products Administration (NMPA) in 2020.\n\nIn 2021, Henlius granted Accord Biopharma the exclusive rights for the development and commercialization of HLX02 in the U.S. and Canada.\n\nThe post Accord BioPharma Announces the Acceptance of BLA for HLX02 (a proposed trastuzumab biosimilar) by FDA appeared first on Big Molecule Watch .",
        "As we previously reported , Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) announced its intent to acquire the global biosimilars business of its long-term partner Viatris, Inc.\n\nThis week, Biocon confirmed completion of its acquisition in a part-cash/part-equity transaction.\n\nUnder the terms of this USD $3.335 billion deal, Biocon paid USD $2 billion up-front in cash, of which $1.2 billion comes from a Sustainability Linked Loan (SLL), making it the largest SLL to pharmaceutical and biomanufacturing companies in the Asia-Pacific region.\n\nBiocon owns 20 biosimilar assets across several therapeutic areas including diabetes, immunology, and cancer, and has commercialized eight biosimilars in Australia, Canada, Europe, Japan, and the U.S. With the acquisition of Viatris, Biocon has now gained full ownership of several biosimilar assets from its prior collaborations with Viatris, including trastuzumab, pegfilgrastim, bevacizumab, insulin glargine, insulin aspart, and pertuzumab.\n\nIn addition, Biocon now owns rights to a biosimilar aflibercept, as well as rights to Viatris\u2019s in-licensed adalimumab and etanercept biosimilars.\n\nAccording to Biocon\u2019s press release, the Viatris and Biocon teams will continue to work together over a two year transition period.\n\nThe post Biocon Biologics Confirms Completion of Multi-Billion Dollar Acquisition of Viatris\u2019 Global Biosimilars Business appeared first on Big Molecule Watch .",
        "According to PWC , \u201c2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels.\u201d\n\nBelow is a recap of the top M&A deals in 2023 that focus on biologics and biosimilars and were covered on the Big Molecule Watch.\n\nCoya Announces Agreement with Dr. Reddy\u2019s Laboratories for Treatment of Neurodegenerative Diseases In March, Coya Therapeutics, Inc. (\u201cCoya\u201d), a biopharmaceutical company based in Houston, announced a worldwide agreement with Dr. Reddy\u2019s Laboratories Ltd. (\u201cDr. Reddy\u2019s\u201d) to license Dr. Reddy\u2019s proposed biosimilar abatacept for the development and commercialization of COYA 302 for the treatment of neurodegenerative conditions.\n\nUnder the agreement, Coya in-licensed Dr. Reddy\u2019s proposed abatacept biosimilar and obtained exclusive rights to develop and commercialize COYA 302 across multiple neurodegenerative diseases in multiple territories, including in North and South America, the EU, United Kingdom, and Japan.\n\nDr. Reddy\u2019s will have exclusive rights to the same in areas outside of these territories.\n\nCoya later reported its 48-week clinical data for a proof-of-concept open-label study in 4 patients with amyotrophic lateral sclerosis (ALS) demonstrating that treatment with COYA 302 appeared to ameliorate disease progression.\n\nIn October, Coya reported new data supporting the mechanism of action of COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (\u201cALS\u201d) at the 22nd Annual Northeast ALS Consortium Meeting.\n\nIn December, Dr. Reddy\u2019s entered into a development and license agreement with Coya for an exclusive license to develop and commercialize COYA 302 for the treatment of ALS in the United States, Canada, the European Union, and the United Kingdom.\u00a0 \n\nUnder the terms of the agreement, Dr. Reddy\u2019s will pay to Coya an upfront payment of $7.5 million, development- and sales-based milestone payments of up to $725.65 million, and low- to mid-teen royalties on sales of COYA 302 in the United States, Canada, the European Union, and the United Kingdom.\n\nMeitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the US\n\nIn September, Meitheal, a biopharmaceutical company based in Chicago, entered into an exclusive licensing deal with Tonghua Dongbao Pharmaceutical Co., Ltd. (\u201cTHDB\u201d) to market three biosimilars of the top selling branded insulins in the United States \u2013 asprat, lispro and glargine.\n\nAll are expected to begin clinical trials in 2024.\n\nThe agreement granted Meitheal and its parent company, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (\u201cNKF\u201d), exclusive rights to commercialize the three biosimilar insulin products upon approval by the FDA, estimated to be on or around 2026.\u00a0 \n\nTHDB and NKF will jointly handle product development and supply.\n\nCoherus Agrees to Acquire a Biosimilar EYLEA Candidate from Klinge Biopharma In January, Coherus BioSciences, Inc. (\u201cCoherus\u201d) announced the execution of a binding term sheet with Klinge Biopharma GmbH (\u201cKlinge Biopharma\u201d) for the exclusive commercialization rights to FYB203, Formycon AG\u2019s (\u201cFormycon\u201d) biosimilar candidate to EYLEA (aflibercept), in the United States.\n\nUnder the binding term sheet, Coherus will make a total upfront payment to Klinge of approximately \u20ac30 million, comprised of cash and Coherus common stock, thirty days after the execution of the definitive agreements.\n\nCoherus will also make other regulatory and launch milestone payments and share profits approximately equally with Klinge in consideration for the commercialization rights to FYB203 in the United States.\n\nFormycon AG is entitled to participate in all Klinge income under the agreement with Coherus in the mid-single to low-double-digit-percentage range.\n\nCoherus intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025, if approved.",
        "As an update to our previous report , Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) announced the successful completion of the transition of the acquired biosimilars business in approximately 120 countries, a year ahead of schedule.\n\nOn December 18, 2023, IAVI, a global nonprofit scientific research organization, and Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, announced that the Bill & Melinda Gates Foundation has awarded IAVI $55 million to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.\n\nThe trial is expected to begin enrolling participants in mid-2024.\n\nOn December 12, 2023, AstraZeneca announced it has agreed to acquire Icosavax, Inc., a company that develops vaccines using a protein virus-like particle (VLP) platform.\n\nIcosavax says that its lead investigational vaccine candidate is IVX-A12, a combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV), two leading causes of severe respiratory infection and hospitalization in adults 60 years of age and older and those with chronic conditions such as cardiovascular, renal and respiratory disease.\n\nThe post Biosimilar Deals Updates: Biocon, AstraZeneca appeared first on Big Molecule Watch .",
        "Below are some highlights from first quarter 2022 earnings reports recently released by biologics and biosimilars companies: Biogen: Last week, Biogen reported total quarterly revenues of $2,532 million, and biosimilar revenue of $194 million decreased 5% versus the prior year. \u00a0\n\nAs reflected by the assumption in the Company\u2019s Full Year 2022 Financial Guidance, \u201c[t]his decline in revenue reflects increased competition in the biosimilar space \u2013 continued decline in RITUXAN revenue and erosion of TECFIDERA revenue due to generic entry.\u201d\u00a0 \n\nBiogen states that \u201c[t]he Company aims to drive potential return to growth in the biosimilar business as one of the near-term operational priorities\u201d and \u201c[w]hile the Company\u2019s current commercial portfolio of anti-TNF products is likely past the peak of its lifecycle, it currently has four more programs in development and is preparing to launch BYOOVIZ, referencing LUCENTIS \u00ae , in the U.S. in the upcoming months.\u201d\n\nBiogen reported that it completed the sale of the company\u2019s equity stake in the Samsung Bioepis joint venture to Samsung Biologics last month, for a total consideration of up to $2.3 billion. \u00a0\n\nBiogen states that together with Samsung Bioepis, it will continue with their exclusive agreements, including the commercialization of the current biosimilar portfolio including BENEPALI (etanercept), FLIXABI (infliximab), IMRALDI (adalimumab) and the potential filings for SB15 (aflibercerpt) in markets.\u00a0 \n\nIn addition, Biogen and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize XCIMZANE, a proposed biosimilar referencing CIMZIA \u00ae (certolizumab pegol). \u00a0\n\nUnder the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to XCIMZANE and will be the Marketing Authorization Holder.\n\nCoherus:\n\nAt the beginning of May, Coherus Biosciences reported that quarterly revenues, consisting of net sales of UDENYCA \u00ae (pegfilgrastim-cbqv), a biosimilar to NEULASTA \u00ae , was $60.1 million and $83.0 million during the three months ended March 31, 2022 and 2021, respectively. \u00a0\n\nDespite the decline, which the Company states was primarily due to a decrease in the number of units of UDENYCA \u00ae sold as well as a lower net realized price due to increased competition, Denny Lanfear, Coherus\u2019 CEO, stated that the Company continues to \u201c[m]ake strong progress transforming into an innovative immune-oncology company supported by revenues generated by the diversified commercial portfolio of FDA-approved products, as it prepares for new product launches in 2022 and 2023.\u201d\n\nCoherus said it expects to launch the FDA-approved YUSIMRY (adaliumumab-aqvh), biosimilar to HUMIRA\u00ae, in the United States in 2023, and has discontinued development of CHS-305 (\u201cIBI-305\u201d), an AVASTIN \u00ae (bevacizumab) biosimilar candidate, and is returning IBI-305 rights to Innovent Biologics (Suzhou) Co., Ltd.\u00a0 Coherus also reports that it is currently finalizing the preparations to launch CIMERLI (ranibizumab-ranq), a LUCENTIS \u00ae biosimilar, later this year, if approved, into the $7 billion anti-VEGF ophthalmology market in the United States.\n\nCoherus also reported receiving a complete response letter (\u201cCRL\u201d) for the Biologics License Application (\u201cBLA\u201d) for Toripalimab. \u00a0\n\nCoherus says that, together with partner Shanghai Junshi Biosciences Co., Ltd. (\u201cJunshi Biosciences\u201d), it \u201cplan[s] to resubmit the Toripalimab BLA by mid-summer with an expected six month review\u201d by the FDA and is \u201cpreparing for the commercial launch directly upon approval.\u201d\n\nToripalimab is an anti-PD-1 monoclonal antibody designed to block PD-1 interactions with its ligands, PD-L1 and PD-L2.\n\nTeva: Also at the beginning of May, Teva reported total quarterly revenue of $3.7 billion, and the generic products revenues in North America segment (including biosimilars) were $899 million, a decrease of 15% compared to the first quarter of 2021.",
        "On April 29, 2024, Accord BioPharma, Inc. announced that the U.S. Food and Drug Administration (FDA) approved HERCESSI (trastuzumab-strf).\u00a0 \n\nHERCESSI is a biosimilar to HERCEPTIN (trastuzumab) and is indicated for adjuvant treatment of HER2-overexpressing breast cancer, the treatment of HER2-overexpressing metastatic breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.\u00a0 \n\nChrys Kokino, U.S. president of Accord, said: \u201c[t]he approval of HERCESSI\u2014our first biosimilar to be approved in the U.S.\u2014marks an important milestone for Accord BioPharma in our efforts to improve access for patients[.]\u201d\n\nHERCESSI is the 6 th trastuzumab biosimilar approved by the FDA.\n\nThe post Accord BioPharma, Inc.\n\nAnnounces FDA Approval of HERCESSI (trastuzumab-strf) appeared first on Big Molecule Watch .",
        "Catalent and Abzena both recently announced substantial investments into new biologics facilities.\u00a0 \n\nCatalent is spending up to $160 million to build a new manufacturing facility near Oxford, UK.\u00a0 \n\nCatalent plans to equip the facility with \u201cstate-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced modalities,\u201d\u00a0and hopes to start servicing customer programs from the new facility before the end of 2022.\u00a0 \n\nAccording to Catalent, it has expertise in biosimilar development and manufacturing , with multiple biosimilar products on the market utilizing its technology.\n\nAbzena\u2019s new facility just opened and is in the U.S., near Abzena\u2019s manufacturing center in San Diego.\u00a0 \n\nThe new facility is focused on biologics testing and will offer \u201cAbzena\u2019s partners access to cell-based and PCR safety assays; and viral clearance studies to support their IND, IMPD, BLA and MAA applications.\u201d\u00a0 \n\nAccording to Abzena, with this latest investment, it now offers \u201call services appropriate for research cell banks, characterization of master and working cell banks, end-of-production of cell cultures, and bulk drug substances.\u201d\u00a0 \n\nAbzena had announced last year \u00a0that it had partnered with BioXpress Therapeutics to support the development and manufacture of biosimilars for global customers.\u00a0 \n\nThe opening of the new facility marks Abzena\u2019s sixth site across the globe.\n\nThe post Expanding Operations in Biologics appeared first on Big Molecule Watch .",
        "Insulin Biosimilars: Meitheal Pharmaceuticals, Inc. has announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceuticals Co., Ltd. to commercialize Tonghua Dongbao\u2019s three insulin biosimilars (insulin aspart, insulin lispro, and insulin glargine) in the U.S. market.\u00a0 \n\nMeitheal and Tonghua Dongbao will be jointly responsible for development and supply, with the expectation of achieving FDA approval in 2026.\n\nOncology, Women\u2019s Health, and Respiratory Disease Biosimilars: Abbott has announced an expansion of its agreement with mAbxience Holdings S.L. to commercialize several of Abbott\u2019s oncology, women\u2019s health, and respiratory disease biosimilars for emerging markets in Latin America, Southeast Asia, the Middle East, and Africa.\u00a0 mAbxience, a Fresenius-Kabi majority-owned group, will be responsible for manufacturing and achieving clinical milestones.\u00a0 \n\nAccording to the press release, the first molecules subject to the agreement are expected to launch as early as 2025.\n\nAnti-Tumor Biosimilars: Chime Biologics Ltd., based in China, has entered into a strategic cooperation agreement as an exclusive provider of\u00a0CDMO (contract development and manufacturing organization) services to Kings Pharm Corp., located in Korea, to commercialize Kings Pharm\u2019s anti-tumor biosimilar for the global market. \u00a0\n\nChime Biologics will be responsible for providing cell line development, early process development, global clinical and commercial manufacturing, and registration.\n\nThe post Recent Biosimilar Commercialization Developments appeared first on Big Molecule Watch .",
        "On December 9, 2022, Biogen announced that the FDA has accepted for review an aBLA for BIIB800, Biogen\u2019s tocilizumab biosimilar candidate.\u00a0 \n\nBIIB800 references Genetech\u2019s ACTEMRA product, which is an anti-interleukin-6 receptor monoclonal antibody indicated for moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis and systemic juvenile idiopathic arthritis.\u00a0 \n\nThe FDA\u2019s acceptance follows the EMA\u2019s acceptance of the marketing authorization application for BIIB800 earlier this year.\n\nBiogen\u2019s aBLA is the second BLA to be accepted by FDA for a tocilizumab biosimilar.\u00a0 \n\nAs we previously reported , the FDA accepted for review Fresenius Kabi\u2019s tocilizumab BLA in August 2022.\n\nThe post FDA Accepts Biogen\u2019s aBLA for Tocilizumab appeared first on Big Molecule Watch ."
    ]
}